CalciMedica (NASDAQ:CALC) Director Fred Middleton Buys 248,972 Shares

CalciMedica Inc. (NASDAQ:CALC) Director Fred Middleton acquired 248,972 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were purchased at an average cost of $0.80 per share, with a total value of $199,177.60. Following the completion of the acquisition, the director directly owned 1,063,272 shares in the company, valued at approximately $850,617.60. The trade was a 30.57% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

CalciMedica Stock Performance

CalciMedica stock traded up $0.09 during trading hours on Monday, reaching $0.91. 547,977 shares of the company’s stock traded hands, compared to its average volume of 1,237,462. The firm has a market capitalization of $14.36 million, a price-to-earnings ratio of -0.67 and a beta of 0.97. CalciMedica Inc. has a fifty-two week low of $0.46 and a fifty-two week high of $7.20. The firm’s 50 day moving average is $0.72 and its 200-day moving average is $1.92.

Institutional Investors Weigh In On CalciMedica

Several large investors have recently bought and sold shares of the company. 180 Wealth Advisors LLC boosted its position in shares of CalciMedica by 297.2% during the first quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock worth $68,000 after purchasing an additional 94,650 shares in the last quarter. Boothbay Fund Management LLC bought a new position in CalciMedica during the fourth quarter worth about $506,000. PVG Asset Management Corp bought a new position in CalciMedica during the fourth quarter worth about $302,000. Renaissance Technologies LLC grew its stake in CalciMedica by 45.0% in the first quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock valued at $69,000 after acquiring an additional 39,775 shares during the period. Finally, Envestnet Asset Management Inc. grew its stake in CalciMedica by 58.2% in the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after acquiring an additional 34,386 shares during the period.

Analyst Upgrades and Downgrades

Separately, Oppenheimer lowered their target price on shares of CalciMedica from $20.00 to $10.00 and set an “outperform” rating for the company in a report on Thursday, March 5th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $10.00.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.